To explore the impact of microglial self-renewal on AD pathology, we utilized an established paradigm that partially depletes microglia using PLX5622 (PLX), a colony stimulating factor 1 receptor (CSF1R/c-kit/Flt3) inhibitor, in 3xTg and APP/PS1 mouse models of AD. This evidence concerns the gene FLT3 and Alzheimer disease.